Advertisement
HomeCollectionsCervical Cancer
IN THE NEWS

Cervical Cancer

BUSINESS
By Mara H. Gottfried and Mara H. Gottfried,CONTRIBUTING WRITER | January 15, 2000
Gaithersburg-based Digene Corp. said yesterday that it has come to an agreement with Laboratory Corporation of America Holdings to use its HPV test, which helps detect cervical cancer in women. Vandana K. Bapna, a biotechnology analyst at Hunt Valley-based Offutt Securities, called the deal significant for Digene, a biotechnology company that focuses on DNA and RNA technology for the detection, screening and monitoring of sexually transmitted diseases. "LabCorp is one of the largest reference testing labs in the United States," Bapna said.
Advertisement
BUSINESS
By Rona Kobell and Rona Kobell,SUN STAFF | May 4, 2000
Digene Corp., the Gaithersburg-based maker of medical test kits, announced yesterday that Kaiser Permanente will use its flagship product to screen for cervical cancer. The 10-year-old company's Digital Hybrid Capture HPV test detects the human papillomavirus, a frequent precursor to cervical cancer. The HPV test is one of a handful of products Digene is developing, but it's the most successful so far, said Digene President Charles Fleischman. The test played prominently in Digene's earnings for the quarter ended March 31, which the company also released yesterday.
HEALTH
By Meredith Cohn | January 27, 2012
The percentage of Americans screened for cancer isn't meeting national targets, and the numbers are even worse for minorities, according the first federal study looking at disparities among Asiand and Hispanic groups. The report by the Centers for Disease Control and Prevention and the National Cancer Institute showed breast cancer screening rates were 72.4 percent, below the 81 percent target set in a national health plan called Healthy People 2020.  It was 83 percent for cervical cancer, missing the 93p ercent mark, and colorectal screening was 58.6 percent, missing hte 70.5 percent target.
BUSINESS
By Andrea K. Walker and Andrea K. Walker,SUN STAFF | March 12, 2002
Digene Corp., a maker of medical diagnostic tests, expects the marketing potential of its DNA-based cervical cancer test to increase 10-fold if the U.S. Food and Drug Administration approves expanded use. The Gaithersburg-based company cleared a major hurdle Friday when an FDA advisory panel recommended that Digene's test, with conditions, be used in conjunction with the Pap smear as a primary detector of cervical cancer. The FDA generally follows the advice of its advisory panels, which are made up of outside experts.
NEWS
January 14, 2007
Regular pelvic examinations urged Dr. Andrew Bernstein, health officer for Harford County, is urging women to have regular pelvic exams and pap tests to screen for cervical cancer. January is National Cervical Cancer Awareness Month. Women should also report any of the following symptoms to their physicians immediately: unusual discharge; blood spots or light bleeding other than a normal period; or bleeding or pain after sex, douching or a pelvic exam. The Health Department is sponsoring gynecological exams for women at no cost who meet program guidelines.
NEWS
By Donna E. Boller and Donna E. Boller,Staff Writer | April 6, 1993
Two Carroll County obstetrician-gynecologists are offering Carroll women what could be a chance at a longer life -- free Pap tests to detect possible cervical cancer.Dr. Melvin A. Yeshnik and his partner, Dr. Michael R. Barnett, will provide the tests from noon to 4 p.m. Friday, April 16, and 8 a.m. to noon Saturday, April 17, at their offices in Suite 306 of the Billingslea Medical Building, 542 Washington Road, Westminster.The American Cancer Society reports that approximately 13,000 women are diagnosed with cervical cancer each year and about 7,000 die from it. "In reality, no one in this country should die from cervical cancer" because Pap smears can provide early detection of abnormalities, Dr. Yeshnik said.
HEALTH
By Andrea K. Walker | June 3, 2013
Michael Douglas told the Guardian newspaper recently that his throat cancer was caused by the HPV virus that he contracted performing oral sex over the years. The actor's admission brings attention to a health problem more doctors are seeing. HPV, which is widely known to cause cervical cancer in women, is also causing cancer in men as well. Dr. Kevin J. Cullen, an oncologist who specializes in treating head and neck cancers, recently spoke to The Sun about the growing number of HPV-related cancers doctors are seeing in men. Cullen, the director of the University of Maryland's Marlene and Stewart Greenebaum Cancer Center, said there are precautions that can be taken.
NEWS
By Laura Smitherman and Laura Smitherman,Sun reporter | January 31, 2007
A bill that would require middle-school girls to get a new vaccine against a sexually transmitted virus that causes cervical cancer is being withdrawn over concerns that children already have a tough time getting all the required immunizations. Sen. Delores G. Kelley, a Baltimore County Democrat, said yesterday that she plans to pull a bill she sponsored that calls for all sixth-grade girls to be vaccinated by September 2008. She said some parents and educators were worried about an added requirement after thousands of students, in grades six through nine, were turned away from school this month for failure to get immunized against chickenpox and hepatitis B, as recently required.
BUSINESS
By Julie Bell and Julie Bell,SUN STAFF | May 3, 2001
Digene Corp. said yesterday that strong U.S. sales of its cervical cancer tests drove quarterly revenue up 47 percent, but that costs from a scuttled secondary offering resulted in a loss equal to that of a year ago. The Gaithersburg company lost $1.6 million, or 10 cents per share, for its fiscal third quarter this year and last. The loss this year included about $500,000 - or 3 cents per share - in expenses related to an offering Digene pulled during the market slump in March. Analysts had predicted a loss of 9 cents per share, excluding the one-time costs, according to the average estimate of three analysts surveyed by Zacks Investment Research Inc. Quarterly revenue was $9 million, compared with $6.1 million a year ago. "It's pretty hard to be negative," said H. C. Wainright analyst Ronald Opel, who upgraded shares of Digene from an "accumulate" rating to a "buy" in March.
Baltimore Sun Articles
|
|
|
Please note the green-lined linked article text has been applied commercially without any involvement from our newsroom editors, reporters or any other editorial staff.